Evidence map›Paper›PMID 35666289›Full record

Trial reportInternational urogynecology journal2022

On-demand use of fesoterodine: a new paradigm for extended release antimuscarinics.

Ibrahim Halil Bozkurt, Ertugrul Sefik, Serdar Celik, Arda Yesilova, Omer Koras, Tansu Degirmenci

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in International urogynecology journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Ibrahim Halil BozkurtIzmir Bozyaka Training and Research Hospital, Department of Urology, University of Health Sciences, Izmir, Turkey. ihalilbozkurt@yahoo.com.
Ertugrul SefikDepartment of Urology, Izmir Tinaztepe Galen Hospital, Izmir, Turkey.
Serdar CelikIzmir Bozyaka Training and Research Hospital, Department of Urology, University of Health Sciences, Izmir, Turkey.
Arda YesilovaIzmir Bozyaka Training and Research Hospital, Department of Urology, University of Health Sciences, Izmir, Turkey.
Omer KorasFaculty of Medicine, Department of Urology, Mustafa Kemal University, Hatay, Turkey.
Tansu DegirmenciIzmir Bozyaka Training and Research Hospital, Department of Urology, University of Health Sciences, Izmir, Turkey.
Izmir University · TRSağlık Bilimleri Üniversitesi · TRMustafa Kemal University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introduction and hypothesisWe aimed to compare on-demand and continuous use of fesoterodine 4 mg concerning efficacy and adverse effects.

methodsA total of 100 patients who were diagnosed with non-neurogenic overactive bladder (OAB) syndrome were included in the study. All patients were evaluated with MMSE, ICIQ-SF, SEAPI quality of health and OAB-V8 questionnaires, at the beginning, 1st month and 4th month. Fesoterodine 4 mg was started for treatment. At the end of the 1st month, patients who obtained benefit from the treatment were 1:1 randomized into two groups. In group 1, fesoterodine 4 mg was given 1 × 1 in a standard manner whereas in group 2 patients took the pills on demand. Both groups were evaluated for efficacy and adverse events at 4 months.

resultsFinal analyses included 69 patients. At 4-month follow-up, OAB-V8 scores were significantly improved compared to 1 month in both groups. Again at h months, no difference was detected between the two groups for MMSE, ICIQ-SF and SEAPI scores. In continuous usage group, 4th month MMSE scores were significantly lower than 1st month scores. At 4 months, dry mouth and constipation were lower in the on-demand group compared to continuous usage group.

conclusionsCompared to standard continuous usage, on-demand usage of fesoterodine showed similar efficacy with fewer adverse events.

Indexed as

Benzhydryl CompoundsMuscarinic AntagonistsUrinary Bladder, OveractiveHumansTreatment OutcomeBenzhydryl CompoundsfesoterodineMuscarinic AntagonistsAntimuscarinicsContinuous useFesoterodineOn-demand therapyOveractive bladder

Identifiers

PMID35666289
OpenAlexW4281723469

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.